Disc Medicine
Clinical-stage biopharmaceutical company developing novel therapies to treat patients with serious hematologic diseases by targeting fundamental biological pathways that regulate red blood cell production.
Location
Watertown, Massachusetts, USA
Founded
2017
Investors
1
Categories
therapeutics, biotech, hematology, clinical-stage
Notes
Disc Medicine is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on developing treatments for serious hematologic diseases. The company targets fundamental biological pathways that regulate red blood cell production, including iron metabolism and erythropoiesis.
The company's lead programs target conditions where patients have ineffective red blood cell production, such as beta-thalassemia, polycythemia vera, and myelofibrosis. Disc Medicine is publicly traded on NASDAQ under the ticker IRON.
Team
- John Quisel, J.D., Ph.D. - CEO
- Will Savage - Co-founder & Chief Business Officer
- Brian MacDonald, Ph.D. - Chief Scientific Officer
Additional Research Findings
- Founded in 2017
- Publicly traded: NASDAQ (IRON)
- Investor: 5AM Ventures, Samsara BioCapital, and others
- Focus on hematologic diseases
- Lead programs targeting iron metabolism and erythropoiesis
- Target indications: beta-thalassemia, polycythemia vera, myelofibrosis
- Headquarters in Watertown, Massachusetts
- Multiple clinical-stage programs
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| 5AM Ventures | Menlo Park, USA | biotech-focused | seedseries-a+1 | 8 |